Drug profile · INN
haloperidol
HALOPERIDOL MEDSURGE
haloperidol (HALOPERIDOL MEDSURGE) is a serotonin 2a (5-ht2a) receptor antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — haloperidol
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 4
- Data quality
- 0.89
Quick answer
haloperidol (HALOPERIDOL MEDSURGE) is a serotonin 2a (5-ht2a) receptor antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Serotonin 2a (5-HT2a) receptor antagonist
Primary target: D2-like dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is haloperidol?
haloperidol (HALOPERIDOL MEDSURGE) is a serotonin 2a (5-ht2a) receptor antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for haloperidol?
HALOPERIDOL MEDSURGE is a marketed brand name for haloperidol. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of haloperidol?
haloperidol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.